posted on 2017-02-17, 15:05authored byBarbara Tabisz, Werner Schmitz, Michael Schmitz, Tessa Luehmann, Eva Heusler, Jens-Christoph Rybak, Lorenz Meinel, Juliane E. Fiebig, Thomas D. Mueller, Joachim Nickel
The
regenerative potential of bone is strongly impaired in pathological
conditions, such as nonunion fractures. To support bone regeneration
various scaffolds have been developed in the past, which have been
functionalized with osteogenic growth factors such as bone morphogenetic
proteins (BMPs). However, most of them required supra-physiological
levels of these proteins leading to burst releases, thereby causing
severe side effects. Site-specific, covalent coupling of BMP2 to implant
materials might be an optimal strategy in order to overcome these
problems. Therefore, we created a BMP-2 variant (BMP2-K3Plk) containing
a noncanonical amino acid (propargyl-l-lysine) substitution
introduced by genetic code expansion that allows for site-specific
and covalent immobilization onto polymeric scaffold materials. To
directly compare different coupling strategies, we also produced a
BMP2 variant containing an additional cysteine residue (BMP2-A2C)
allowing covalent coupling by thioether formation. The BMP2-K3Plk
mutant was coupled to functionalized beads by a copper-catalyzed azide–alkyne
cycloaddition (CuAAC) either directly or via a short biotin-PEG linker
both with high specificity. After exposing the BMP-coated beads to
C2C12 cells, ALP expression appeared locally restricted in close proximity
to these beads, showing that both coupled BMP2 variants trigger cell
differentiation. The advantage of our approach over non-site-directed
immobilization techniques is the ability to produce fully defined
osteogenic surfaces, allowing for lower BMP2 loads and concomitant
higher bioactivities, for example, due to controlled orientation toward
BMP2 receptors. Such products might provide superior bone healing
capabilities with potential safety advantages as of homogeneous product
outcome.